Tumor cell populations differ in angiogenic activity: A model system for spontaneous angiogenic switch can tell us why

Journal of the National Cancer Institute

Volumn 98, Issue 5, 2006, Pages 294-295

  Narazaki, Masashi ^a   Tosato, Giovanna ^a,b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOGENIC FACTOR; ANGIOPOIETIN; ANGIOSTATIN; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CYTOTOXIC AGENT; ENDOSTATIN; EPHRIN; EPHRIN RECEPTOR; EPHRIN RECEPTOR B2; EPHRIN RECEPTOR B4; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 2; INTERLEUKIN 8; JAGGED1; MONOCYTE CHEMOTACTIC PROTEIN 1; NEOGENIN; NETRIN; NEXAVAR; NOTCH RECEPTOR; PLACENTAL GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR; SCATTER FACTOR; SEMAPHORIN; SORAFENIB; STROMAL CELL DERIVED FACTOR 1; THROMBOSPONDIN 1; TRANSFORMING GROWTH FACTOR; UNINDEXED DRUG; VASCULOTROPIN;

BREAST CARCINOMA; CANCER CELL CULTURE; CANCER GROWTH; CANCER MODEL; CANCER STEM CELL; CARCINOGENESIS; CELL SUBPOPULATION; DRUG EFFICACY; EDITORIAL; GENE SWITCHING; GLIOBLASTOMA; MOLECULAR BIOLOGY; NONHUMAN; ONCOGENE; OSTEOSARCOMA; PHENOTYPIC VARIATION; PRIORITY JOURNAL; PROTEIN SYNTHESIS; SCID MOUSE; TUMOR CELL; TUMOR SUPPRESSOR GENE; TUMOR VASCULARIZATION;

CELL LINE, TUMOR; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 33644779842     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djj099     Document Type: Editorial

References (30)

1. Algire G, Chalkley H, Legallais F, Park H. Vascular reactions of normal and malignant tissues in vivo. I. Vascular reactions of mice to wounds and to normal and neoplastic transplants. J Natl Cancer Inst 1945;6:73-85.
2. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
3. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86:353-64.
4. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003;3:401-10.
5. Dameron KM, Volpert OV, Tainsky MA, Bouck N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 1994;265:1582-4.
6. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999;399:271-5.
7. Rak J, Filmus J, Finkenzeller G, Grugel S, Marme D, Kerbel RS. Oncogenes as inducers of tumor angiogenesis. Cancer Metastasis Rev 1995;14:263-77.
8. Jain RK. Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. Science 2005;307:58-62.
9. Black WC, Welch HG. Advances in diagnostic imaging and overestimations of disease prevalence and the benefits of therapy. N Engl J Med 1993;328: 1237-43.
10. Naumov GN, Bender E, Zurakowski D, Kang S-Y, Sampson D, Flynn E, et al. A model of human tumor dormancy: An angiogenic switch from the nonangiogenic phenotype. J Natl Cancer Inst 2006;98:316-25.
11. Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature 2005; 438:967-74.
12. Noseda M, Chang L, McLean G, Grim JE, Clurman BE, Smith LL, et al. Notch activation induces endothelial cell cycle arrest and participates in contact inhibition: Role of p21Cip1 repression. Mol Cell Biol 2004;24:8813-22.
13. Williams CK, Li JL, Murga M, Harris AL, Tosato G. Upregulation of the Notch ligand Delta-like 4 inhibits VEGF-induced endothelial cell function. Blood 2005 Oct 11; [Epub ahead of print].
14. Watanabe K, Hasegawa Y, Yamashita H, Shimizu K, Ding Y, Abe M, et al. Vasohibin as an endothelium-derived negative feedback regulator of angiogenesis. J Clin Invest 2004;114:898-907.
15. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, et al. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell 1997;88:277-85.
16. O'Reilly MS, Holmgren L, Chen C, Folkman J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med 1996;2:689-92.
17. Pike SE, Yao L, Jones KD, Cherney B, Appella E, Sakaguchi K, et al. Vasostatin, a calreticulin fragment, inhibits angiogenesis and suppresses tumor growth. J Exp Med 1998;188:2349-56.
18. Sund M, Hamano Y, Sugimoto H, Sudhakar A, Soubasakos M, Yerramalla U, et al. Function of endogenous inhibitors of angiogenesis as endothelium-specific tumor suppressors. Proc Natl Acad Sci U S A 2005;102:2934-9.
19. Nikolova G, Lammert E. Interdependent development of blood vessels and organs. Cell Tissue Res 2003;314:33-42.
20. LeCouter J, Lin R, Ferrara N. Endocrine gland-derived VEGF and the emerging hypothesis of organ-specific regulation of angiogenesis. Nat Med 2002;8:913-7.
21. Weinstein BM. Vessels and nerves: Marching to the same tune. Cell 2005; 120:299-302.
22. Carmeliet P, Tessier-Lavigne M. Common mechanisms of nerve and blood vessel wiring. Nature 2005;436:193-200.
23. Klagsbrun M, Eichmann A. A role for axon guidance receptors and ligands in blood vessel development and tumor angiogenesis. Cytokine Growth Factor Rev 2005;16:535-48.
24. Noren NK, Lu M, Freeman AL, Koolpe M, Pasquale EB. Interplay between EphB4 on tumor cells and vascular ephrin-B2 regulates tumor growth. Proc Natl Acad Sci U S A 2004;101:5583-8.
25. Bielenberg DR, Hida Y, Shimizu A, Kaipainen A, Kreuter M, Kim CC, et al. Semaphorin 3F, a chemorepulsant for endothelial cells, induces a poorly vascularized, encapsulated, nonmetastatic tumor phenotype. J Clin Invest 2004;114:1260-71.
26. Scadden DT. Cancer stem cells refined. Nat Immunol 2004;5:701-3.
27. Jones RJ, Matsui WH, Smith BD. Cancer stem cells: Are we missing the target? J Natl Cancer Inst 2004;96:583-5.
28. Ponti D, Costa A, Zaffaroni N, Pratesi G, Petrangolini G, Coradini D, et al. Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res 2005;65:5506-11.
29. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J. Vascular-specific growth factors and blood vessel formation. Nature 2000;407:242-8.
30. Folkman J. Tumor angiogenesis: Therapeutic implications. N Engl J Med 1971;285:1182-6.